|
EP0107278B1
(en)
|
1982-08-04 |
1989-11-15 |
National Research Development Corporation |
Molecular cloning of the gene for human anti-haemophilic factor ix
|
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4770999A
(en)
|
1985-04-22 |
1988-09-13 |
Genetics Institute, Inc. |
High yield production of active Factor IX
|
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
FR2638643B1
(fr)
|
1988-11-09 |
1991-04-12 |
Transgene Sa |
Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
JP3131222B2
(ja)
|
1991-12-24 |
2001-01-31 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ギャップを有する２′修飾オリゴヌクレオチド
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
WO1994026877A1
(en)
|
1993-05-17 |
1994-11-24 |
The Regents Of The University Of California |
Ribozyme gene therapy for hiv infection and aids
|
|
JP4285766B2
(ja)
|
1994-03-23 |
2009-06-24 |
オハイオ ユニバーシティ |
緻密にした核酸および細胞へのデリバリ
|
|
GB9408717D0
(en)
|
1994-05-03 |
1994-06-22 |
Biotech & Biolog Scien Res |
DNA sequences
|
|
JPH10500310A
(ja)
|
1994-05-19 |
1998-01-13 |
ダコ アクティーゼルスカブ |
淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ
|
|
EP1005376B1
(en)
|
1997-03-14 |
2010-11-03 |
The Children's Hospital of Philadelphia |
Compositions for use in gene therapy for treatment of hemophilia
|
|
WO1998054345A1
(en)
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
|
US6531298B2
(en)
|
1997-07-21 |
2003-03-11 |
The University Of North Carolina At Chapel Hill |
Factor IX antihemophilic factor with increased clotting activity
|
|
EP1626091B1
(en)
|
2000-06-01 |
2014-07-23 |
University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
ATE318923T1
(de)
|
2000-06-01 |
2006-03-15 |
Univ North Carolina |
Doppelsträngige parvovirus-vektoren
|
|
US20030143740A1
(en)
|
2001-10-15 |
2003-07-31 |
Christine Wooddell |
Processes for transposase mediated integration into mammalian cells
|
|
US20030108524A1
(en)
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
|
PT1453547T
(pt)
|
2001-12-17 |
2016-12-28 |
Univ Pennsylvania |
Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
|
|
AU2003247962B2
(en)
|
2002-07-18 |
2008-06-12 |
Monsanto Technology Llc |
Methods for using artificial polynucleotides and compositions thereof to reduce transgene silencing
|
|
US7579176B2
(en)
|
2003-10-15 |
2009-08-25 |
Newlight Technologies, Llc |
Method for the production of polyhydroxyalkanoic acid
|
|
WO2006036502A2
(en)
|
2004-09-22 |
2006-04-06 |
St. Jude Children's Research Hospital |
Improved expression of factor ix in gene therapy vectors
|
|
ES2465996T3
(es)
|
2006-05-25 |
2014-06-09 |
Sangamo Biosciences, Inc. |
Métodos y composiciones para la inactivación genética
|
|
EP2423307A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IV polypeptides and use thereof for treatment
|
|
ES2535877T3
(es)
|
2006-06-19 |
2015-05-18 |
Asklepios Biopharmaceutical, Inc. |
Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
|
|
DE602008003684D1
(de)
|
2007-04-26 |
2011-01-05 |
Sangamo Biosciences Inc |
Gezielte integration in die ppp1r12c-position
|
|
CA2720903C
(en)
|
2008-04-14 |
2019-01-15 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
SG191561A1
(en)
|
2008-08-22 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
TR201813067T4
(tr)
|
2008-09-15 |
2018-09-21 |
Uniqure Biopharma B V |
Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem.
|
|
EP2352369B1
(en)
|
2008-12-04 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
EP2419511B1
(en)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
EP2456877A4
(en)
|
2009-07-24 |
2012-05-30 |
Sigma Aldrich Co Llc |
METHOD OF GENOMIC PROCESSING
|
|
JP2013500726A
(ja)
|
2009-07-31 |
2013-01-10 |
バイエル・ヘルスケア・エルエルシー |
改変第ｉｘ因子ポリペプチドおよびその使用
|
|
ES2751916T3
(es)
|
2010-02-08 |
2020-04-02 |
Sangamo Therapeutics Inc |
Semidominios de escisión genomanipulados
|
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
WO2011146885A2
(en)
|
2010-05-21 |
2011-11-24 |
Virxsys Corporation |
Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing
|
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
|
US9175280B2
(en)
|
2010-10-12 |
2015-11-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating hemophilia B
|
|
EP2675484B1
(en)
|
2011-02-14 |
2018-05-30 |
The Children's Hospital of Philadelphia |
Improved aav8 vector with enhanced functional activity and methods of use thereof
|
|
CA2848417C
(en)
|
2011-09-21 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
CA3099582A1
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
EP2839013B1
(en)
|
2012-04-18 |
2020-08-26 |
The Board of Trustees of the Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
NZ701693A
(en)
|
2012-04-18 |
2017-02-24 |
The Children’S Hospital Of Philadelphia |
Composition and methods for highly efficient gene transfer using aav capsid variants
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
EP3196301B1
(en)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of monogenic diseases
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
AU2013335451C1
(en)
|
2012-10-23 |
2024-07-04 |
Toolgen Incorporated |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
|
US9255250B2
(en)
|
2012-12-05 |
2016-02-09 |
Sangamo Bioscience, Inc. |
Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
EP2928303A4
(en)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
CN107879960B
(zh)
|
2013-03-08 |
2021-06-22 |
诺华股份有限公司 |
用于传递活性成分的脂质和脂质组合物
|
|
EP2994531B1
(en)
|
2013-05-10 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CN105683376A
(zh)
*
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
CN105683379A
(zh)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
|
CN105940013B
(zh)
|
2013-12-09 |
2020-03-27 |
桑格摩生物科学股份有限公司 |
用于治疗血友病的方法和组合物
|
|
CN105813814B
(zh)
|
2013-12-12 |
2017-09-12 |
3M创新有限公司 |
制备聚合物多层膜的方法
|
|
EP3083556B1
(en)
|
2013-12-19 |
2019-12-25 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2015127439A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
US20150376586A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
CA2954791C
(en)
|
2014-07-14 |
2025-11-18 |
The Regents Of The University Of California |
CRISPR/CAS TRANSCRIPTIONAL MODULATION
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
WO2016106121A1
(en)
|
2014-12-23 |
2016-06-30 |
Syngenta Participations Ag |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
KR20230156800A
(ko)
|
2015-03-03 |
2023-11-14 |
더 제너럴 하스피탈 코포레이션 |
변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
MX390848B
(es)
|
2015-06-23 |
2025-03-21 |
Childrens Hospital Philadelphia |
Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3159407A1
(en)
|
2015-10-23 |
2017-04-26 |
Silence Therapeutics (London) Ltd |
Guide rnas, methods and uses
|
|
MY189674A
(en)
|
2015-10-28 |
2022-02-24 |
Sangamo Therapeutics Inc |
Liver-specific constructs, factor viii expression cassettes and methods of use thereof
|
|
BR112018008971A2
(pt)
*
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
|
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CN109715801B
(zh)
*
|
2015-12-01 |
2022-11-01 |
克里斯普治疗股份公司 |
用于治疗α1抗胰蛋白酶缺乏的材料和方法
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
US20190075770A1
(en)
|
2015-12-18 |
2019-03-14 |
Japan Science And Technology Agency |
Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
|
LT3436077T
(lt)
|
2016-03-30 |
2025-06-25 |
Intellia Therapeutics, Inc. |
Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
|
|
AU2017257274B2
(en)
|
2016-04-19 |
2023-07-13 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN105950626B
(zh)
|
2016-06-17 |
2018-09-28 |
新疆畜牧科学院生物技术研究所 |
基于CRISPR/Cas9获得不同毛色绵羊的方法及靶向ASIP基因的sgRNA
|
|
EP4321623A3
(en)
|
2016-07-15 |
2024-05-15 |
Salk Institute for Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CA3035534A1
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
US20180127786A1
(en)
|
2016-09-23 |
2018-05-10 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing
|
|
KR102712926B1
(ko)
|
2016-10-20 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
파브리병의 치료를 위한 방법 및 조성물
|
|
SG10202106058WA
(en)
|
2016-12-08 |
2021-07-29 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
AU2017374042C1
(en)
|
2016-12-09 |
2024-07-11 |
Acuitas Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
TWI851534B
(zh)
|
2016-12-22 |
2024-08-11 |
美商英特利亞醫療公司 |
用於治療α-１抗胰蛋白酶缺乏症之組合物及方法
|
|
US11597947B2
(en)
|
2016-12-29 |
2023-03-07 |
Asc Therapeutics Inc. |
Gene editing method using virus
|
|
PT3568483T
(pt)
|
2017-01-10 |
2025-11-18 |
Childrens Medical Res Institute |
Polinucleótidos e vetores para a expressão de transgenes
|
|
JP7215716B2
(ja)
|
2017-01-13 |
2023-01-31 |
学校法人自治医科大学 |
肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター
|
|
BR112019015355A2
(pt)
|
2017-01-26 |
2020-05-19 |
Sangamo Therapeutics Inc |
modificação genética de células b
|
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
JP2020519272A
(ja)
|
2017-05-09 |
2020-07-02 |
エモリー ユニバーシティー |
凝固因子変異体及びその使用
|
|
CN110945127B
(zh)
|
2017-05-22 |
2024-07-12 |
武田药品工业株式会社 |
用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
|
|
JP7123982B2
(ja)
|
2017-06-15 |
2022-08-23 |
ツールゲン インコーポレイテッド |
肝臓において目的のタンパク質を発現するためのプラットフォーム
|
|
US11981898B2
(en)
|
2017-06-16 |
2024-05-14 |
Applied Stemcell, Inc. |
Gene editing methods with increased knock-in efficiency
|
|
GB2566453B
(en)
|
2017-09-12 |
2021-01-13 |
Univ Of Northumbria At Newcastle |
Impactor for aerosol component collection
|
|
WO2019067910A1
(en)
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
|
|
US20230140670A1
(en)
|
2017-09-29 |
2023-05-04 |
Intellia Therapeutics, Inc. |
Formulations
|
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
|
CA3082450A1
(en)
*
|
2017-11-21 |
2019-05-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
EP3728598A1
(en)
|
2017-12-21 |
2020-10-28 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Nucleic acid sequence replacement by nhej
|
|
EP3787694A4
(en)
|
2018-04-29 |
2022-05-18 |
University of Massachusetts |
RAAV-MEDIATED NUCLEASE-ASSOCIATED VECTOR INTEGRATION (RAAV-NAVI)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
AU2019282824C1
(en)
|
2018-06-08 |
2026-04-23 |
Intellia Therapeutics, Inc. |
Modified guide RNAS for gene editing
|
|
WO2019239361A1
(en)
|
2018-06-14 |
2019-12-19 |
Novartis Ag |
Method for sequence insertion using crispr
|
|
CA3103528A1
(en)
|
2018-06-19 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
|
|
AU2019293286A1
(en)
|
2018-06-28 |
2021-01-07 |
Crispr Therapeutics Ag |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
|
MA53252A
(fr)
*
|
2018-08-10 |
2021-09-15 |
Logicbio Therapeutics Inc |
Thérapie génique non perturbatrice pour le traitement d'un mma
|
|
SG11202103917VA
(en)
*
|
2018-10-16 |
2021-05-28 |
Blueallele Llc |
Methods for targeted insertion of dna in genes
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|
|
WO2020082047A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
|
US20200270617A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|
|
AU2019360270B2
(en)
|
2018-10-18 |
2025-08-07 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX.
|